Y-mAbs Therapeutics

General Information


We are a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. We have a broad and advanced product pipeline, including two pivotal-stage product candidates—naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively. We are developing naxitamab for the treatment of pediatric patients with relapsed or refractory, or R/R, high-risk neuroblastoma, or NB, and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system, or CNS, leptomeningeal metastases, or LM, from NB. NB is a rare and almost exclusively pediatric cancer that develops in the sympathetic nervous system and CNS/LM is a rare and usually fatal complication of NB in which the disease spreads to the membranes, or meninges, surrounding the brain and spinal cord in the CNS.

Employees: 29
Founded: 2015
Contact Information
Address 230 Park Avenue, 33rd Floor, New York, NY 10169, US
Phone Number (212) 847-9841
Web Address http://www.ymabs.com
View Prospectus: Y-mAbs Therapeutics
Financial Information
Market Cap $489.4mil
Revenues $0 mil (last 12 months)
Net Income $-30.9 mil (last 12 months)
IPO Profile
Symbol YMAB
Exchange NASDAQ
Shares (millions): 6.0
Price range $16.00 - $16.00
Est. $ Volume $96.0 mil
Manager / Joint Managers BofA Merrill Lynch/ Cowen/ Canaccord Genuity
CO-Managers BTIG
Expected To Trade: 9/21/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change